SIGA TECHNOLOGIES INC
No SEC Form 4 filings for $SIGA in the last 30 days.
See all $SIGA insider activity →SIGA Technologies (NASDAQ:SIGA) received a $15M contract from Canada for oral TPOXX, an antiviral for smallpox. The deal runs until 2031, with $9M committed in the first three years. This is the second such contract, following a $14M agreement in 2020. The medication is approved by Health Canada for smallpox treatment.
Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.
SIGA Technologies (SIGA) reported a 65% profit drop year-over-year, with Q2 revenue at $41M and net income at $12.5M. The company completed a major government contract and paid a $0.6 special dividend. Despite declines, SIGA remains profitable and diversifies its customer base.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning SIGA (SIGA TECHNOLOGIES INC). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent SIGA coverage spans financial news, earnings and market movers.
The award extends SIGA’s smallpox countermeasure revenue visibility and supports continued Canadian Armed Forces access to TPOXX.
Small upside from sector exposure.
Earnings miss and profit decline may pressure the stock, but the special dividend and contract completion provide some support.
The disclosed government orders are a tangible revenue/capex visibility catalyst for Sigma, tied to a specific counter-drone platform deployment.
Near-term earnings are pressured by delivery timing and contract transition, but the call highlights concrete milestones for FDA submissions and a targeted international order.
AlphAI scores every news story that mentions SIGA with an AI model for sentiment and relevance, and aggregates insider trades from SIGA TECHNOLOGIES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
SIGA Technologies (NASDAQ:SIGA) received a $15M contract from Canada for oral TPOXX, an antiviral for smallpox. The deal runs until 2031, with $9M committed in the first three years. This is the second such contract, following a $14M agreement in 2020. The medication is approved by Health Canada for smallpox treatment.
3 min readNovavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.
2 min readSIGA Technologies (SIGA) reported a 65% profit drop year-over-year, with Q2 revenue at $41M and net income at $12.5M. The company completed a major government contract and paid a $0.6 special dividend. Despite declines, SIGA remains profitable and diversifies its customer base.
2 min readIndrajaal Autonomous Defense Systems and Sigma Advanced Systems said the Government of India placed about ₹155 crore of orders for the Indrajaal Ranger anti-drone patrol vehicle. The orders include ~₹145 crore for border security via an Indrajaal-Sigma consortium and ~₹10 crore for urban police/VVIP protection. Sigma shares last traded at Rs. 626.85 on the BSE.
4 min readSIGA Technologies reported Q2 2026 results in an earnings call. Total revenue fell to $41.0M from $81.1M due to delivery timing. Operating income was $13.9M and net income $12.5M, with diluted EPS $0.17. Cash was $117.6M, zero debt. Management said the final IV TPOXX order under the 19C contract was completed and a new U.S. contract is targeted after slower HHS transitions.
6 min readSIGA Technologies’ Q2 earnings call said $24 million of IV TPOXX sales reflected completion of a 2025 order under the 19C contract, with international sales linked to an Asia-Pacific order received in 2026. Management said U.S. multiyear TPOXX procurement talks continue, with BARDA funding and a March 2027 target for a new international contract.
7 min readSIGA TECHNOLOGIES INC (SIGA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026 • $37 Million of TPOXX Sales Generated in the Second Quarter • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, August 6, 2026 (GLOBENEWSWIRE) -- SIGA Technologies, Inc. (SIGA)
4 min readSigma Advanced Systems said it won a USD 104.9 million export order from a North American customer to manufacture and supply 147,000 units of 155mm base bleed artillery shell bodies over the next 6 to 12 months. The company cited prior contracts for 155mm fuzes and M107 shell bodies and said the shells reduce drag to extend range. Sigma shares last traded at Rs. 521.45 on BSE.
4 min readSIGA TECHNOLOGIES INC (SIGA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ef20075854_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SIGA TECHNOLOGIES, INC. 2010 STOCK INCENTIVE PLAN (as amended and restated, effective May 23, 2017) ARTICLE I General 1.1 Purpose The purpose of the SIGA Technologies, Inc. 2010 Stock Incentive Plan (the “Plan”) is to esta
3 min readSIGA Technologies, Inc. (NASDAQ:SIGA) has announced a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record on April 7, 2026. This dividend matches the previous year's special dividend and reflects the company's strong balance sheet and focus on shareholder value, despite trading near its 52-week low. The company, a commercial-stage pharmaceutical firm, recently reported a Q4 2025 loss but demonstrated overall annual strength with a net income of $23 million and a solid cash balance.
2 min read
